Sai Life Sciences Doubles Profit as Discovery Revenue Triples
Sai Life Sciences reported a 29% revenue rise and doubled profits in FY26. Discovery income tripled to Rs 775 crore, driving its high valuation.
Key points
- FY26 revenue grew 29% while net profit more than doubled for Sai Life Sciences.
- Discovery revenue tripled from Rs 274 crore in FY22 to Rs 775 crore in FY26.
- The company faces a trailing P/E above 90x with a market cap of Rs 33,650 crore.
Sai Life Sciences reported FY26 results showing 29% revenue growth and more than doubled net profit. The company aims to convert its expanding drug pipeline into earnings to justify its high valuation. The Indian Express reported these figures during a period of strong operational momentum.
Discovery revenue triples to Rs 775 crore
The discovery arm drove significant growth this year. Revenue in this segment rose from Rs 274 crore in FY22 to Rs 775 crore in FY26. This nearly threefold increase highlights the company's strategic shift. Sai now provides integrated chemistry and biology services to more clients.
Over 65% of discovery customers now use multiple services. This sticky relationship reduces reliance on single projects. The company also grew its CDMO segment. Manufacturing revenue more than doubled to reach Rs 1,417 crore in FY26.
Valuation requires rapid pipeline conversion
Sai’s market capitalization stands at approximately Rs 33,650 crore. The share price is around Rs 1,584. Investors face a trailing P/E ratio above 90x. This premium valuation demands consistent execution. Any delay in converting molecules to sales could impact shareholder returns.
The business operates as a funnel. It starts with discovery and moves to manufacturing. More molecules are progressing through this pipeline. Successful conversion is critical for maintaining current margins. The company must utilize new capacity effectively to sustain growth.
Capex plan targets capacity expansion
Sai plans a capital expenditure of Rs 1,100–1,300 crore. This investment aims to add production capacity. Management expects the second half of FY27 to be stronger. New capacity should help ramp up commercial programs. This expansion supports the goal of serving more late-stage projects.
Q1 FY27 results showed double-digit growth. Both revenue and profitability continued to expand. This momentum supports the company's long-term strategy. The focus remains on capturing a larger share of customer budgets. The company seeks to be involved earlier in drug development.
